Hemispherx Biopharma, Inc. (HEB) Starts Presentation at 2015 Marcum MicroCap Conference

Hemispherx Biopharma is engaged in the manufacture and clinical development of new drug entities for the treatment of seriously debilitating disorders especially life-threatening viruses. The company’s flagship products include Alferon® N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including chronic fatigue syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases including cancers. For more information, visit the company’s website at www.hemispherx.net.